Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL-RA: VIB4920 With a TNF-alpha Inhibitor in Rheumatoid Arthritis
NCT05306353Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dazodalibep in rheumatoid arthritis (RA), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2023; status: terminated.
02
Drugs
dazodalibep
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05306353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306353.